View clinical trials related to Mass Casualty Incident.
Filter by:This interventional study aims to investigate whether Virtual Reality (VR) compared to traditional education and training, can enhance the correct triage abilities of nursing students in simulated mass casualty incidents (MCI). The primary research question seeks to answer if VR compared to Standard education supports students' ability to triage correctly in a simulated MCI situation. Additionally, this study aims to address the following secondary questions: Does VR compared to standard education have an effect on the time to triage in a simulated MCI situation? And, does VR compared to Standard education have an effect on theoretical knowledge retention concerning triage in MCI situations? In the interventional group, participants will utilize VR for MCI training and learning, while the control group will undergo standard education, including lectures and paper exercises. The researchers will compare the two groups of nursing students to assess whether VR yields better outcomes in MCI triage education.
The study's overarching aim is to determine whether Enzymatically Augmented Subcutaneous Infusion (EASI) can assist in out-of-hospital situations characterized by mismatch between need for, and ability to achieve, access to the vascular compartment. One mechanism for providing access to the vascular compartment, subcutaneous infusion, is facilitated by administration of hyaluronidase; the hyaluronidase hydrolyzes hyaluronan the major subcutaneous diffusion barrier. Hyaluronidase thus increases local dispersion and absorption of subcutaneously administered drugs and fluids. The EASI Access study is intended to be the first out-of-hospital study assessing FDA-approved Chinese hamster ovary-derived recombinant hyaluronidase (the recombinant product is hereafter referred to by the shorter brand name, Hylenex). The EASI Access will test some fundamental principles and will facilitate design and implementation of follow-up investigations (e.g. extension of access to non-ALS providers). For example, we will attempt to show that EASI access is simple, effective, and has few or no downsides as compared to IV access.